These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 21131612)

  • 1. Tumour cryoablation combined with palliative bypass surgery in the treatment of unresectable pancreatic cancer: a retrospective study of 142 patients.
    Li J; Chen X; Yang H; Wang X; Yuan D; Zeng Y; Wen T; Yan L; Li B
    Postgrad Med J; 2011 Feb; 87(1024):89-95. PubMed ID: 21131612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The outcome of cryoablation in treating advanced pancreatic cancer: a comparison with palliative bypass surgery alone.
    Song ZG; Hao JH; Gao S; Gao CT; Tang Y; Liu JC
    J Dig Dis; 2014 Oct; 15(10):561-9. PubMed ID: 24958092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Surgical palliation for pancreatic cancer. The 25-year experience of a single reference centre].
    Popiela T; Kedra B; Sierzega M; Kubisz A
    Zentralbl Chir; 2002 Nov; 127(11):965-70. PubMed ID: 12476370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas.
    Müller MW; Friess H; Köninger J; Martin D; Wente MN; Hinz U; Ceyhan GO; Blaha P; Kleeff J; Büchler MW
    Am J Surg; 2008 Feb; 195(2):221-8. PubMed ID: 18154768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined biliary and gastric bypass procedures as effective palliation for unresectable malignant disease.
    Mann CD; Thomasset SC; Johnson NA; Garcea G; Neal CP; Dennison AR; Berry DP
    ANZ J Surg; 2009 Jun; 79(6):471-5. PubMed ID: 19566872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery.
    Donahue TR; Isacoff WH; Hines OJ; Tomlinson JS; Farrell JJ; Bhat YM; Garon E; Clerkin B; Reber HA
    Arch Surg; 2011 Jul; 146(7):836-43. PubMed ID: 21768431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
    Berger AC; Meszoely IM; Ross EA; Watson JC; Hoffman JP
    Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of palliative biliary and gastric bypass surgery for pancreatic head carcinoma in 126 patients.
    van Wagensveld BA; Coene PP; van Gulik TM; Rauws EA; Obertop H; Gouma DJ
    Br J Surg; 1997 Oct; 84(10):1402-6. PubMed ID: 9361599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unresectable pancreatic carcinoma: correlating length of survival with choice of palliative bypass.
    Di Fronzo LA; Cymerman J; Egrari S; O'Connell TX
    Am Surg; 1999 Oct; 65(10):955-8. PubMed ID: 10515542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microscopically incomplete resection offers acceptable palliation in pancreatic cancer.
    Kuhlmann K; de Castro S; van Heek T; Busch O; van Gulik T; Obertop H; Gouma D
    Surgery; 2006 Feb; 139(2):188-96. PubMed ID: 16455327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of survival in patients treated for malignant biliary obstruction caused by unresectable pancreatic head cancer: surgical versus non-surgical palliation.
    Kim HO; Hwang SI; Kim H; Shin JH
    Hepatobiliary Pancreat Dis Int; 2008 Dec; 7(6):643-8. PubMed ID: 19073412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of curative versus palliative surgical treatment for stage III pancreatic cancer patients.
    Kymionis GD; Konstadoulakis MM; Leandros E; Manouras A; Apostolou A; Alexiou D; Katsaragakis S; Androulakis G
    J R Coll Surg Edinb; 1999 Aug; 44(4):231-5. PubMed ID: 10453145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer.
    Waraya M; Yamashita K; Katagiri H; Ishii K; Takahashi Y; Furuta K; Watanabe M
    Ann Surg Oncol; 2009 May; 16(5):1231-40. PubMed ID: 19263172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective study on radiofrequency ablation locally advanced pancreatic cancer.
    Casadei R; Ricci C; Pezzilli R; Serra C; Calculli L; Morselli-Labate AM; Santini D; Minni F
    Hepatobiliary Pancreat Dis Int; 2010 Jun; 9(3):306-11. PubMed ID: 20525559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
    Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
    Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complications of palliative hepaticojejunostomy and gastrojejunostomy in unresectable periampullary cancer: patient- and disease-related risk factors.
    Räty S; Sand J; Piironen A; Nordback I
    Hepatogastroenterology; 2006; 53(67):133-7. PubMed ID: 16506392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ?].
    Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Yoneda M; Abe Y; Inamori M; Kirikoshi H; Kubota K; Saito S; Nakajima A
    Gan To Kagaku Ryoho; 2008 Jan; 35(1):65-70. PubMed ID: 18195530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic head carcinoma: clinical analysis of 189 cases.
    Hua YP; Liang LJ; Peng BG; Li SQ; Huang JF
    Hepatobiliary Pancreat Dis Int; 2009 Feb; 8(1):79-84. PubMed ID: 19208521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting factors for survival of patients with unresectable pancreatic cancer: a management guideline.
    Fujino Y; Suzuki Y; Ajiki T; Tanioka Y; Ku Y; Kuroda Y
    Hepatogastroenterology; 2003; 50(49):250-3. PubMed ID: 12630033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Value of combined therapy in pancreatic cancer with a poor prognosis: analysis of 233 clinical cases].
    Wang Y; Zhao P; Wang CF; Shan Y; Zhao DB; Tian YT; Sun YM; Che X; Zhang JW
    Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(34):2381-5. PubMed ID: 20137689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.